Aptevo Therapeutics (APVO) EBITDA Margin (2015 - 2022)
Aptevo Therapeutics (APVO) posted EBITDA Margin of 180.19% for Q1 2022, down 63.46% sequentially from 110.23% in Q4 2021, and up 10432.0% YoY from N/an in Q1 2021.
Aptevo Therapeutics (APVO) EBITDA Margin (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported EBITDA Margin for 8 years, with the latest figure at 180.19% in Q1 2022.
- Quarterly EBITDA Margin rose 10432.0% year-over-year to 180.19% in Q1 2022, while the trailing twelve-month figure through Dec 2022 was 919.75% (down 74565.0% YoY) and the FY2022 annual result came in at 919.75%, down 74565.0% from the prior year.
- EBITDA Margin eased to 180.19% in Q1 2022 per APVO's latest filing, from 110.23% in the prior quarter.
- Over five years, EBITDA Margin peaked at 87.88% in Q4 2019 and troughed at 1439.11% in Q2 2020.
- A 5-year average of 294.42% and a median of 183.99% in 2021 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2020 and 2021: EBITDA Margin tumbled 126389 bps in 2020, then surged 125512 bps in 2021.
- Over 5 years, EBITDA Margin stood at 227.7% in 2018, then surged by 61 bps to 87.88% in 2019, then slumped by 227 bps to 287.36% in 2020, then soared by 62 bps to 110.23% in 2021, then plunged by 63 bps to 180.19% in 2022.
- According to Business Quant data, EBITDA Margin over the past three periods registered 180.19%, 110.23%, and 153.42% for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -180.19% |
| Dec 31, 2021 | -110.23% |
| Sep 30, 2021 | -153.42% |
| Jun 30, 2021 | -183.99% |
| Mar 31, 2021 | -284.51% |
| Dec 31, 2020 | -287.36% |
| Sep 30, 2020 | -426.93% |
| Jun 30, 2020 | -1,439.11% |
| Dec 31, 2019 | -87.88% |
| Sep 30, 2019 | -127.17% |
| Jun 30, 2019 | -175.22% |
| Mar 31, 2019 | -162.92% |
| Sep 30, 2018 | -227.70% |
| Jun 30, 2018 | -238.10% |
| Mar 31, 2018 | -331.64% |
| Sep 30, 2017 | -167.66% |
| Jun 30, 2017 | -415.46% |
| Mar 31, 2017 | -566.34% |
| Dec 31, 2016 | -165.96% |
| Sep 30, 2016 | -3,214.67% |